SciELO - Scientific Electronic Library Online

 
vol.32 número3Implantación del Comprehensive Medication Management en pacientes costarricenses con enfermedad renal crónicaEstudio de terapia secuencial en mieloma múltiple en recaída índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de la OFIL

versão On-line ISSN 1699-714Xversão impressa ISSN 1131-9429

Resumo

FAJRELDINES, A et al. Incidence of adverse events to chemotherapy using two detection methods: characterization and associated health costs. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.3, pp.275-281.  Epub 25-Set-2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20220003000011.

Despite the progress it has made in the survival of cancer patients, the appearance of new chemotherapeutic agents and new combinations, these have brought with them numerous adverse effects that can compromise treatment and, consequently, the prognosis of the disease.

Objectives:

To know the incidence of adverse events associated with chemotherapy (AE), characterize them and analyze their economic implications using two detection tools.

Materials and methods:

Longitudinal cut incidence study.

Results:

350 patients were studied. Mean age: 56.9, median: 43.4, range: 19-85. The number of patients with AD was: 323 in the five years. The cumulative incidence (AI) was: 0.923 that is 92.3% patients in 5 years and the incidence density (DI) was 0.186 in five years that is 18.6%. The number of ADES in the sample was 1,601 with manual review, a mean of 4.57 EA/patient in the total sample. The AE indicators were: 457.42 AE/100 discharges, and 118.57 AE/1,000 hospitalized patient days. 152.47 EA/1,000 doses of oncology administered were detected. With the GTT review, 1,578 AE were found, a mean of 4.50 AE/patient. The AE indicators were: 450.8 AE/100 discharges, and 126.64 AE/1,000 patient days and 141.45 AE/1,000 doses of oncological drugs administered. The costs invoiced with and without events are USD 5,343.75 vs. 15,287.5. The two detection tools have a similar detection capacity in terms of number of AE, but the complete medical history review without triggers takes six times the time that the trigger tool takes.

Conclusions:

The incidence of adverse cancer events is high, the GTT tool is useful compared to the complete review of medical records to find AE, the costs of hospitalization with events in relation to without events are significantly higher. The most frequent reactions are dermatological, and those that affect the blood system, among others.

Palavras-chave : Adverse drug events; chemotherapy; Global Trigger Tool.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )